drugset
Drugs / MVA-NP+M1
last change Mar 2022 re-read 3 minutes ago

MVA-NP+M1

Vaccine

Developed for
influenza
Investigated by
Barinthus Biotherapeutics · Clinical Network Services (CNS) Pty Ltd

Trials 1

today NCT03880474 · Ph 2
20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT03880474 Mar → Oct 2019 influenza Barinthus Biotherapeutics Terminated Missed primary

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as MVA-NP+M1 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03880474 ↗
Modality Vaccine “a recombinant viral-vectored vaccine (modified vaccinia Ankara expressing virus nucleoprotein and matrix protein 1; MVA-NP+M1)” PMID 35305317 ↗ Mar 2022
Route Intramuscular “receive one dose of 1·5 × 108 plaque-forming units of MVA-NP+M1 or saline (placebo) intramuscularly” PMID 35305317 ↗ Mar 2022